Sensitivity analyses
One-way showed that the probability of hospitalization has the highest impact on the outcome, but MS was the dominant strategy in all range of probabilities analyzed. The results of PSA are graphically represented in the cost-effectiveness plane, figure 3 . 53.82% of simulations were graphed in quadrant 2 (lower cost, high QALYs), and 45.97% in quadrant 1 of this plane (high cost, high QALYs). The 95% CI for the cost per patient treated with FeNO-SC, and with SC were US$ 1331 to 1335 and US$ 1449 to 1454. The 95% CI for QALYs per patient was 0.93 to 0.94 and 0.91 to 0.92 respectively. The net monetary benefits of FeNO-SC was higher than SC (US$ 16591 vs US$ 16885). The expected net benefit with perfect information US$ 16885.9 and the expected value of perfect information were: US$ 0.074. The Cost-effectiveness acceptability curve shows that the probability that FeNO-SC provides a more cost-effective use of resources compared with standard therapy exceeds 99% for all willingness to pay thresholds. The population expected value of perfect information (EVPIP) for the threshold of US$ 20 was US$ 1030015.